This post was originally published on this site Although triple therapies with Revlimid (lenalidomide) should be prioritized in patients with relapsed or refractory multiple myeloma (RRMM), combining this therapy with dexamethasone could be effective if the patients respond partially after the first treatment cycle, according to new research. The study, “Response to First Cycle Is…
This post was originally published on this site Adding Tecentriq (atezolizumab) to standard chemotherapy reduced the risk of disease worsening or death in previously untreated patients with locally advanced or metastatic urothelial cancer, according to early results of a Phase 3 trial Also, according to Genentech — the company marketing Tecentriq — the analysis showed encouraging…
This post was originally published on this site Eagle Pharmaceuticals is preparing a pilot study that may pave the way for a pivotal clinical trial evaluating its new formulation of fulvestrant as a treatment for estrogen receptor (ER)-positive breast cancer. The company believes its new formulation will block estrogen receptors more effectively than AstraZeneca‘s original formulation, approved…
This post was originally published on this site Blood levels of certain molecules— metabolites and amino acids — may help to identify people with Alzheimer’s disease who are more likely to improve their cognitive skills in response to aerobic exercise, a study suggests. These results were shared in the poster “Plasma Metabolites to Predict Response to Exercise…
This post was originally published on this site A new statistical analysis of Finland’s nationwide cardiac sarcoidosis (CS) registry found that sudden cardiac death plays a significant role in the outcome of CS patients, affirming the importance of risk assessment in this patient population. The study, “Sudden death in cardiac sarcoidosis: an analysis of nationwide…
This post was originally published on this site Medicare will provide nationwide coverage for CAR T-cell therapies, an innovative anti-cancer treatment, for certain types of lymphoma and leukemia, the Centers for Medicare & Medicaid Services (CMS) has announced. Medicare will pay for this costly therapy to all cancer patients falling under the labels approved by…
This post was originally published on this site A Phase 1/2 trial testing the advanced tumors treatment candidate THOR-707 has begun dosing patients in Australia — and has been cleared by the U.S. Food and Drug Administration to enroll participants in the U.S. Australia is the first country recruiting patients for the global HAMMER trial…
This post was originally published on this site My boss brought it up a couple of times, but the rule was clear: Polite people don’t mention it. Norma didn’t follow that rule. She’d walk down the hall fanning herself, her sweater flung over the nearest chair and her skin suddenly flushed red. “I’m having a…
This post was originally published on this site Men with metastatic castration-resistant prostate cancer (mCRPC) given Lynparza (olaparib), a breast and ovarian cancer treatment, went a clinically meaningful longer time without disease progression or death compared to those given standard treatment with Xtandi (enzalutamide) or Zytiga (abiraterone) in a Phase 3 trial. The multicenter, open-label PROfound study…
This post was originally published on this site Using an approach called Optimal Just-in-Time (JIT) has shortened the start of patient enrollment in clinical trials of both solid tumors and blood cancers from eight months to only two weeks. Among other advantages, the methodology also enabled the recruitment of more diverse patient populations than traditional…
